GlassScriptPhysician profile
Ayaaz Ismail
NPI 1528167947
$6,529.80
in general payments reported to CMS, 2019-2025
32 companies · $1,022 in 2025
The $1,022 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $802 · 2020: $287 · 2021: $509 · 2022: $1,306 · 2023: $1,356 · 2024: $1,248 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,526.94 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,393.46 | 2019-2025 | |
| Janssen Biotech, INC. | $772.66 | 2020-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $591.17 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Merck Sharp & Dohme LLC | $300.43 | 2019-2024 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $268.61 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $216.59 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $196.43 | 2019-2023 | Linzess |
| Genzyme Corporation | $175.45 | 2022-2023 | |
| Qol Medical, LLC | $167.37 | 2019-2024 | Sucraid, Sucraid |
| Celgene Corporation | $150.78 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $150.47 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $149.55 | 2022-2025 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $144.51 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $125.31 | 2022-2023 | |
| Dova Pharmaceuticals | $124.99 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $114.09 | 2024-2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $54.13 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $51.75 | 2024-2025 | Rezdiffra, Resmetirom |
| Braintree Laboratories, INC. | $49.35 | 2019-2023 | Sutab |
| Boston Scientific Corporation | $43.14 | 2019 | |
| Celltrion USA INC. | $42.04 | 2024-2025 | Vegzelma |
| Novo Nordisk INC | $38.49 | 2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $33.86 | 2019-2020 | |
| Orphalan INC | $33.46 | 2024 | Cuvrior |
| Lucid Diagnostics INC. | $21.41 | 2022 | |
| Intra-Sana Laboratories | $21.33 | 2021 | |
| Ardelyx, INC. | $18.91 | 2023 | Ibsrela |
| Mallinckrodt Hospital Products INC. | $17.75 | 2023 | Terlivaz |
| Ethicon US, LLC | $16.83 | 2019 | |
| Shionogi INC | $16.58 | 2019 | |
| Exact Sciences Corporation | $15.67 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $13.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayaaz Ismail listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.